[Skip to Content]
[Skip to Content Landing]
Views 462
Citations 0
Invited Commentary
July 30, 2020

Faricimab Combination Therapy for Sustained Efficacy in Neovascular Age-Related Macular Degeneration

Author Affiliations
  • 1Vanderbilt Eye Institute, Nashville, Tennessee
  • 2Vanderbilt University Medical Center, Nashville, Tennessee
  • 3School of Medicine, Vanderbilt University, Nashville, Tennessee
JAMA Ophthalmol. Published online July 30, 2020. doi:10.1001/jamaophthalmol.2020.2723

The advent of anti–vascular endothelial growth factor (anti-VEGF) therapy has represented a paradigm shift in the treatment of neovascular age-related macular degeneration (nAMD). However, anti-VEGF injections require frequent office visits for administration to maintain visual acuity gains, placing a considerable treatment burden on patients, caregivers, and the health care system. Achieving sustained efficacy with fewer injections has been a major focus of research into new therapeutic options for nAMD.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words